Syros Pharmaceuticals (SYRS) CEO Nancy Simonian on Q1 2021 Results - Earnings Call Transcript

SA Transcripts
153.96K Followers

Q1: 2021-05-06 Earnings Summary

EPS of -$2.30 beats by $2.60
 | Revenue of $4.83M (102.90% Y/Y) beats by $2.16M

Syros Pharmaceuticals, Inc. (OTC:SYRS) Q1 2021 Earnings Conference Call May 6, 2021 8:30 AM ET

Company Participants

Naomi Aoki - VP, CC&IR
Nancy Simonian - CEO
David Roth - CMO
Joe Ferra - CFO
Eric Olson - CSO

Conference Call Participants

Phil Nadeau - Cowen & Company
Jason Butler - JMP Securities
Mark Breidenbach - Oppenheimer
Zegbeh Jallah - ROTH Capital Partners
Ted Tenthoff - Piper Sandler

Operator

Good morning. And welcome to Syros Pharmaceuticals First Quarter 2021 Financial Results Conference Call. At this time, all participants are in a listen-only mode. This call is being webcast live on the Investors & Media section of Syros' website at www.syros.com. Please be advised that today's call is being recorded. Following the formal remarks, we will open up the call up for your questions.

At this time, I would like to turn the call over to Naomi Aoki, Vice President of Corporate Communications and Investor Relations at Syros.

Naomi Aoki

Thank you. This morning we issued a press release with our first quarter 2021 financial results, along with anticipated future milestones and recent accomplishment. This release is available on the Investors & Media section of Syros' website at www.syros.com. We will begin the call with prepared remarks by Dr. Nancy Simonian, our Chief Executive Officer; and Joe Ferra, our Chief Financial Officer. We will then open the call for question. Dr. David Roth, our Chief Medical Officer; and Dr. Eric Olson, our Chief Scientific Officer are also on the call and will be available for Q&A.

Before we begin and I would like to remind everyone that statements we make on this conference call will include forward-looking statements. Actual events or results could differ materially from those expressed or implied by any forward-looking statement as a result of various risks, uncertainties and other factors, including

Recommended For You

About SYRS Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on SYRS